Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA, MIT Collaborate On Development Of Active Drug Safety Surveillance Tool

Executive Summary

FDA is working with the Massachusetts Institute of Technology's Center for Biomedical Innovation to develop an active drug safety surveillance system
Advertisement

Related Content

FDA’s Implementing Visionary: A Conversation With COO John Dyer
FDA’s Implementing Visionary: A Conversation With COO John Dyer
Public/Private Partnership Is Best Vehicle For Active Rx Surveillance System
Greater Regulation Of Pharma By Congress Could Be Risky – FDA’s Gottlieb
Gottlieb’s New Year’s Wish List: Risk Management Plans Out, Science In
FDA Opposes Enzi/Kennedy Drug Safety Bill; Action More Likely Through PDUFA
FDA Opposes Enzi/Kennedy Drug Safety Bill; Action More Likely Through PDUFA
“Drug Watch” Sent Back To The Drawing Board; FDA Turning To MedWatch?
FDA Postmarketing Surveillance System Adds Kaiser Retrospective Database
FDA Postmarketing Surveillance System Adds Kaiser Retrospective Database
Advertisement
UsernamePublicRestriction

Register

PS047512

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel